CL2022001085A1 - Formulación de anticuerpo que contiene crizanlizumab - Google Patents

Formulación de anticuerpo que contiene crizanlizumab

Info

Publication number
CL2022001085A1
CL2022001085A1 CL2022001085A CL2022001085A CL2022001085A1 CL 2022001085 A1 CL2022001085 A1 CL 2022001085A1 CL 2022001085 A CL2022001085 A CL 2022001085A CL 2022001085 A CL2022001085 A CL 2022001085A CL 2022001085 A1 CL2022001085 A1 CL 2022001085A1
Authority
CL
Chile
Prior art keywords
crizanlizumab
formulation containing
antibody formulation
antibody
formulations
Prior art date
Application number
CL2022001085A
Other languages
English (en)
Spanish (es)
Inventor
Juergen Sigg
Fabian Bickel
Lina Boado
Dirk Chelius
Francois Griaud
Caroline Hilbert
Frieder Kroener
Rajsekhar Paul
Maja Anko
Aljosa Jelenko
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2022001085A1 publication Critical patent/CL2022001085A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CL2022001085A 2019-10-30 2022-04-28 Formulación de anticuerpo que contiene crizanlizumab CL2022001085A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962927720P 2019-10-30 2019-10-30
US201962927716P 2019-10-30 2019-10-30
US201962933692P 2019-11-11 2019-11-11
US201962936269P 2019-11-15 2019-11-15

Publications (1)

Publication Number Publication Date
CL2022001085A1 true CL2022001085A1 (es) 2023-02-03

Family

ID=73544317

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001085A CL2022001085A1 (es) 2019-10-30 2022-04-28 Formulación de anticuerpo que contiene crizanlizumab

Country Status (19)

Country Link
US (1) US20220378912A1 (cg-RX-API-DMAC7.html)
EP (1) EP4051236A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023501155A (cg-RX-API-DMAC7.html)
KR (1) KR20220092917A (cg-RX-API-DMAC7.html)
CN (1) CN114828826A (cg-RX-API-DMAC7.html)
AU (1) AU2020373017B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022008097A2 (cg-RX-API-DMAC7.html)
CA (1) CA3158921A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001085A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022005207A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP22033601A (cg-RX-API-DMAC7.html)
IL (1) IL292403A (cg-RX-API-DMAC7.html)
JO (1) JOP20220097A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022005044A (cg-RX-API-DMAC7.html)
MY (1) MY209141A (cg-RX-API-DMAC7.html)
PE (1) PE20221276A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022551041A1 (cg-RX-API-DMAC7.html)
TW (1) TWI893018B (cg-RX-API-DMAC7.html)
WO (1) WO2021087050A1 (cg-RX-API-DMAC7.html)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2662091T3 (pl) 2006-12-01 2019-05-31 Novartis Ag Przeciwciała skierowane przeciwko selektynie P i sposoby ich zastosowania do leczenia chorób zapalnych
JOP20190101A1 (ar) * 2016-11-03 2019-05-05 Novartis Ag أنظمة علاج
US10646569B2 (en) * 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
RU2020132460A (ru) * 2018-03-08 2022-04-08 Новартис Аг Применение антитела к p-селектину

Also Published As

Publication number Publication date
JP2023501155A (ja) 2023-01-18
TWI893018B (zh) 2025-08-11
MX2022005044A (es) 2022-05-16
CO2022005207A2 (es) 2022-05-10
MY209141A (en) 2025-06-24
CA3158921A1 (en) 2021-05-06
AU2020373017A1 (en) 2022-05-19
PE20221276A1 (es) 2022-09-05
CN114828826A (zh) 2022-07-29
US20220378912A1 (en) 2022-12-01
JOP20220097A1 (ar) 2023-01-30
KR20220092917A (ko) 2022-07-04
ECSP22033601A (es) 2022-05-31
WO2021087050A1 (en) 2021-05-06
IL292403A (en) 2022-06-01
EP4051236A1 (en) 2022-09-07
TW202128221A (zh) 2021-08-01
BR112022008097A2 (pt) 2022-08-02
PH12022551041A1 (en) 2023-04-24
AU2020373017B2 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
CO2021005987A2 (es) Compuestos de anillo fusionado
CL2019001686A1 (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas.
SV2018005643A (es) Composiciones de insulina de rapida accion
MX2020001885A (es) Formulaciones de daptomicina.
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
AR109685A1 (es) Composiciones de nanopartículas y métodos para fabricarlas y usarlas
MX2021004331A (es) Composiciones estables de semaglutida y usos de las mismas.
MX2016000405A (es) Metodos y formulaciones que permiten la modulacion de respuestas inmunitarias relacionadas con la administracion de un farmaco biofarmaceutico.
MX2017000764A (es) Formulacion acuosa que comprende paracetamol e ibuprofeno.
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
DOP2021000170A (es) Formulacion de anticuerpos terapeuticos
CO2020016008A2 (es) Formulación de proteína de fusión estable
CL2020002519A1 (es) Composiciones de erenumab y usos de las mismas
MY191980A (en) Formulations containing an extract of echinacea and linoleic acid derivatives
CO2022005737A2 (es) Formulación estable de anticuerpo de integrina
BR112017024039B8 (pt) Piroglutamato de vortioxetina, composições farmacêuticas e gel compreendendo o mesmo, método para preparar um gel, e usos do piroglutamato de vortioxetina para fabricação de um medicamento ou gel
BR112016026660A2 (pt) ?produto extemporâneo para cuidados cosméticos e/ou dermatológicos, e, kit de preparação extemporânea de uma composição cosmética e/ou dermatológica?
MX2022005317A (es) Prevencion de formacion de particulas visibles en soluciones acuosas de proteina.
CO2019014831A2 (es) Nuevas formulaciones orales de belinostat
ECSP21079422A (es) Método para preparar formulaciones de péptidos estables
MX374705B (es) Composiciones que comprenden anakinra.
CL2019000123A1 (es) Preparaciones de vitaminas que contienen galato de propilo.
ECSP22033601A (es) Formulación de anticuerpo que contiene crizanlizumab
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
BR112022012436A2 (pt) Formulação compósita e método para preparar a formulação compósita